Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Active, not recruiting · NCT04214067 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, carcinosarcoma, endometrial endometrioid adenocarcinoma, mixed neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04214067 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| NRG Oncology | 93 |
280 results · Page 1 of 12
Research sites
Swipe the table sideways for more columns.